Alphabet’s AI drug discovery startup Isomorphic Labs is reportedly close to raising more than $2 billion in new funding led by Thrive Capital. The fresh cash is set to expand its AI drug design engine and support global growth, reinforcing Alphabet’s push to commercialize advanced AI technology beyond research labs.
Thrive Capital has launched Thrive Eternal, a permanent-capital vehicle designed to acquire and manage major assets for decades. Its first proposed partnership is tied to the San Francisco Giants, signaling Thrive’s push beyond technology into iconic sports franchises. The deal is not final yet and will require league approval before any stake is secured.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Bob Iger, the former Disney CEO who has exited the company, is rejoining Thrive Capital as an advisor. He already holds a stake in the venture firm and previously served as a venture partner there, making his return less of a debut and more of a homecoming for the investor behind major media turns.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
